"I am proud to have been part of the team that developed our proprietary, innovative platform technologies for oral delivery and recombinant expression of peptides, and their application to our therapeutic programs. The new Unigene now brings in an aggressive business focus, vision, and strategic realignment that enables us to apply our technologies to a much wider range of peptide molecules and closer to fulfilling the promise of our scientific achievements for the benefit of patients, our investors, and our employees alike."
- Nozer Mehta, Chief Scientific Officer
"The Biologics Price Competition and Innovation Act created a new landscape for the development of peptide therapies. Unigene's experience and formulation expertise place us in an excellent position to maximize this opportunity, and deliver oral agents to patients by building on our proven track record of registration success and excellence in quality systems."
- Roxanne Tavakkol, VP, Global Regulatory Affairs and Quality Assurance
"Our formulation development and manufacturing capabilities help our partners get into the clinic by reducing lead time, risk and cost. We offer our clients comprehensive CMC services, including assay development and qualification, tablet and capsule pharmaceutical development and GMP manufacturing of early phase clinical trial supplies. Our goal is to deliver the highest quality services on expedited timelines, thus ensuring the success of our client’s oral delivery programs."
- Paul Shields, VP, Manufacturing Operations
"Unigene truly has a distinctive competence when it comes to the design and formulation of orally delivered therapeutic peptides. By that, I mean we possess unique capabilities that allow us to make inroads into target markets gaining advantage over competitors. When we license our Peptelligence™ technology platforms to our partners, we pass on our distinctive competence to them, in turn enabling these companies to perform better than their competitors. As such, Unigene truly is a peptide powerhouse and the partner of choice in the therapeutic market space!"
- Ashleigh Palmer, President and CEO
